Kardigan Inc(KARD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 31.67% | Shs Outstand | 93.5M | Perf Week | -1.77% |
| Market Cap | 1.20B | Forward P/E | - | EPS next Y | - | Insider Trans | 23.45% | Shs Float | 63.9M | Perf Month | -11.05% |
| Enterprise Value | 0.61B | PEG | - | EPS next Q | -1.01 | Inst Own | 61.81% | Short Float | 6.96% | Perf Quarter | -39.71% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 159.87% | Short Ratio | 8.5 | Perf Half Y | - |
| Sales | - | P/B | 1.94 | EPS next 5Y | - | ROA | - | Short Interest | 4.45M | Perf YTD | -21.23% |
| Book/sh | 6.59 | P/C | 2 | EPS past 3/5Y | - | ROE | - | 52W High | -52.59% ($27.00) | Perf Year | - |
| Cash/sh | 6.39 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 4.66% ($12.23) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.04% 9.23% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.72 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 36.17 | Recom | 1.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.72 | Sales Q/Q | - | SMA20 | -7.66% ($13.86) | Beta | - | Target Price | $39.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/11 | SMA50 | -24.9% ($17.04) | Rel Volume | 1.3 | Prev Close | $12.74 |
| Employees | 210 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -582.66% - | SMA200 | -33.6% ($19.28) | Avg Volume(3M) | 0.52M | Price | $12.8 |
| IPO | 2026/6/18 | Option/Short | Yes/Yes | Trades | 3509 | Volume | 679,827 | Change | 0.47% |
Cardigen is a US clinical-stage biotech company developing treatments for cardiovascular diseases. It holds multiple drug candidates targeting cardiac conditions such as inherited dilated cardiomyopathy, aortic valve stenosis, and hypertension, and is pursuing unmet medical needs through a pipeline specialized in the field of heart disease.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded more than usual. That is 130% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 61.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #145 of 595 in the industry
Based on market cap of $1B.
FAQ
What kind of company is KARD?
KARD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KARD?
The market cap of KARD is approximately $1.2B, ranking 2,454 within its sector.
What is the 52-week high and low for KARD?
KARD has recorded a 52-week high of $27.00 and a low of $12.23.
